Several catalytic events for novel obesity pipeline drugs that go beyond targeting GLP-1 receptors are expected this year.
| Novel Agents | APHD-012 | Undisclosed | Aphaia Pharma | Switzerland | Phase II results | 1Q |
|---|---|---|---|---|---|---|
| Novel Agents | S-309309 | MGAT2 Inhibitor | Shionogi & Co | Japan | Phase II results | 1H |
| Novel Agents | bimagrumab | ACTR2 Antagonist | Versanis Biopharmaceuticals | United States | Phase II results | 1H |
| Novel Agents | cagrisema (cagrilinitide + semaglutide) | CALCR/RAMP1/2/3 Agonist + GLP-1RA | Novo Nordisk | Denmark | Phase III results | 2H |
| Dual Agonists (non GIPR/GLP-1R) | dapiglutide | GLP-1/GLP-2 Agonist | Zealand Pharma | Denmark | Phase II results | 1H |
| Dual GIPR/GLP-1R Agonists | VK2735 | GIPR/GLP-1R Agonist | Viking Therapeutics | United States | Phase II results | 1H |
| Dual GIPR/GLP-1R Agonists | CT-388 | GIPR/GLP-1R Agonist | Carmot Therapeutics | United States | Phase I/II results | 1H |
| Dual GIPR/GLP-1R Agonists | CT-868 | GIPR/GLP-1R Agonist | Carmot Therapeutics | United States | Phase II results | 2H |
| Dual GIPR Antagonist /GLP-1R Agonist | AMG-133 | GIPR Antagonist /GLP-1R Agonist | Amgen | United States | Phase II results | 2H |